{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:34:09Z","timestamp":1792784049814,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"European Community\u05f3s Seventh Framework Programme","award":["602805"],"award-info":[{"award-number":["602805"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.euroneuro.2017.05.005","type":"journal-article","created":{"date-parts":[[2017,5,31]],"date-time":"2017-05-31T16:02:39Z","timestamp":1496246559000},"page":"795-808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":143,"title":["Cannabinoids in attention-deficit\/hyperactivity disorder: A randomised-controlled trial"],"prefix":"10.1016","volume":"27","author":[{"given":"Ruth E.","family":"Cooper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Seegobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Tye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonna","family":"Kuntsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Asherson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2017.05.005_bib1","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S2215-0366(16)30032-3","article-title":"Adult attention-deficit hyperactivity disorder: key conceptual issues","volume":"3","author":"Asherson","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib2","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1177\/0269881110382465","article-title":"Does intravenous 9-tetrahydrocannabinol increase dopamine release? A SPET study","volume":"25","author":"Barkus","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib3","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1176\/ajp.152.11.1652","article-title":"Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity","volume":"152","author":"Biederman","year":"1995","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib4","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.eurpsy.2014.06.003","article-title":"Objective QbTest and subjective evaluation of stimulant treatment in adult attention deficit-hyperactivity disorder","volume":"30","author":"Bijlenga","year":"2015","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib5","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.biopsych.2013.05.027","article-title":"Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms","volume":"75","author":"Bloomfield","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/0269881113519509","article-title":"Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology","volume":"28","author":"Bolea-Alama\u00f1ac","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib7","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1007\/s00213-015-3915-0","article-title":"Further human evidence for striatal dopamine release induced by administration of \u22069-tetrahydrocannabinol (THC): selectivity to limbic striatum","volume":"232","author":"Bossong","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib8","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/npp.2008.138","article-title":"Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum","volume":"34","author":"Bossong","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib9","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1212\/WNL.0b013e3181a2e8f6","article-title":"Altered anandamide degradation in attention-deficit hyperactivity disorder","volume":"72","author":"Centonze","year":"2009","journal-title":"Neurologyogy"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib10","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.biopsych.2013.10.005","article-title":"Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit\/hyperactivity disorder: evidence from a systematic review and a meta-analysis","volume":"76","author":"Coghill","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib11","unstructured":"Conners, C.K., Erhardt, D., Sparrow, E., 1999 Conners\u05f3 Adult ADHD Rating Scales (CAARS)."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib70","doi-asserted-by":"crossref","unstructured":"Craig, P., Dieppe, P., Macintyre, S., Mitchie, S., Nazareth, I., Petticrew, M., 2008. Developing and evaluating complex interventions: the new Medical research council guidance. BMJ 337, 979\u2013983. http:\/\/dx.doi.org\/10.1136\/bmj.a1655.","DOI":"10.1136\/bmj.a1655"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib12","unstructured":"Crane, N., Schuster, R., Fusar-Poli, P., Gonzalez, R., 2013. Effects of Cannabis on Neurocognitive Functioning: Recent Advances, Neurodevelopmental Influences, and Sex Differences. http:\/\/dx.doi.org\/10.1007\/s11065-012-9222-1.Effects."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/ADM.0b013e31820c23fa","article-title":"An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions","volume":"5","author":"Crean","year":"2011","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib14","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1038\/sj.npp.1301643","article-title":"Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis","volume":"33","author":"D\u2019Souza","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/7854_2012_200","article-title":"Neural and behavioural endophenotypes in ADHD","author":"del Campo","year":"2012","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jsat.2003.09.005","article-title":"The cannabis youth treatment (CYT) study: main findings from two randomized trials","volume":"27","author":"Dennis","year":"2004","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib17","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/epi.12631","article-title":"Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders","volume":"55","author":"Devinsky","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S2215-0366(14)00117-5","article-title":"Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study","volume":"2","author":"Di Forti","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib19","first-page":"1","article-title":"Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment","volume":"0","author":"Englund","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib20","first-page":"1","article-title":"Attention-deficit\/hyperactivity disorder","volume":"1","author":"Faraone","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib21","unstructured":"FDA, 2006. FDA Asks Attention-Deficit Hyperactivity Disorder (ADHD) Drug Manufacturers to Develop Patient Medication Guides (WWW Document). URL \u3008http:\/\/www.fda.gov\/drugs\/drugsafety\/postmarketdrugsafetyinformationforpatientsandproviders\/ucm107918.htm\u3009."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib22","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/09595230310001613976","article-title":"Being stoned: a review of self-reported cannabis effects","volume":"22","author":"Green","year":"2003","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib23","unstructured":"Group, I.E.W., 1994. Dose-response Information to Support Drug Registration: E4."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib24","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1469-7610.2011.02489.x","article-title":"An epidemiological study of ADHD symptoms among young persons and the relationship with cigarette smoking, alcohol consumption and illicit drug use","volume":"53","author":"Gudjonsson","year":"2012","journal-title":"J. Child Psychol. Psychiatry Allied Discip."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00004583-199701000-00014","article-title":"Prevalence and implications of attention deficit hyperactivity disorder among adolescents in treatment for substance abuse","volume":"36","author":"Horner","year":"1997","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/1471-244X-12-223","article-title":"Rates of undiagnosed attention deficit hyperactivity disorder in London drug and alcohol detoxification units","volume":"12","author":"Huntley","year":"2012","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib27","unstructured":"Iberstadt, F., 2012. Qb Test Technical Manual. Qbtech AB, Stockholm, Sweden."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib28","first-page":"1","article-title":"Guidelines for selecting the covariance structure in mixed model analysis","volume":"30","author":"Kincaid","year":"2005","journal-title":"Analysis"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib29","unstructured":"Kooij, J.J.S., Francken, M.H., 2010. Diagnostic interview for ADHD in adults. The DIVA Foundation. The Hague, The Netherlands."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib30","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.cpr.2011.01.006","article-title":"Prospective association of childhood attention-deficit\/hyperactivity disorder (ADHD) and substance use and abuse\/dependence: a meta-analytic review","volume":"31","author":"Lee","year":"2011","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib31","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/hup.579","article-title":"Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects","volume":"19","author":"Leonard","year":"2004","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib32","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/bjc.1993.402","article-title":"Intention to treat - who should use ITT?","volume":"68","author":"Lewis","year":"1993","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib33","unstructured":"Lisdahl, K., Wright, N., Kirchner-Medina, C., Kristin, E., Maple, B.S., Shollenbarger, S., 2014. Considering Cannabis: the Effects of Regular Cannabis Use on Neurocognition in Adolescents and Young Adults. Vol. 1, pp. 144\u2013156. http:\/\/dx.doi.org\/10.1016\/j.pestbp.2011.02.012.Investigations."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib34","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3109\/10826084.2013.841251","article-title":"Subtypes of attention deficit-hyperactivity disorder (ADHD) and cannabis use","volume":"49","author":"Loflin","year":"2014","journal-title":"Subst. Use Misuse"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib35","unstructured":"Marijuana and Medicine, 2004. The Need for a Science-Based ApproachHearing before the Subcommittee on Criminal Justice, Drug Policy and Human Resources, U.S. House of Representatives, Second Session Sess."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib36","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1038\/sj.npp.1300176","article-title":"Effects of THC on behavioral measures of impulsivity in humans","volume":"28","author":"McDonald","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0006-3223(02)01671-2","article-title":"Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies","volume":"53","author":"Michelson","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib38","unstructured":"Milz, E., Grotenhermen, F., 2015. Successful therapy of treatment resistant adult ADHD with cannabis: experience from a medical practice with 30 patients. In: Proceedings of the Abstract Book of the Cannabinoid Conference. 17\u201319 September, Sestri Levante, Italy, p. 85."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib39","doi-asserted-by":"crossref","first-page":"e0156614","DOI":"10.1371\/journal.pone.0156614","article-title":"\u201cI use weed for my ADHD\u201d: a qualitative analysis of online forum discussions on cannabis use and ADHD","volume":"11","author":"Mitchell","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/jnnp.63.1.89","article-title":"A self report measure of affective lability","volume":"63","author":"Moore","year":"1997","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib41","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1017\/S0033291711001322","article-title":"Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being","volume":"42","author":"Morgan","year":"2012","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib42","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1192\/bjp.bp.110.077503","article-title":"Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study","volume":"197","author":"Morgan","year":"2010","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib43","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.pain.2007.08.028","article-title":"Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial","volume":"133","author":"Nurmikko","year":"2007","journal-title":"Pain"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib44","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1162\/jocn.2009.21008","article-title":"Two types of action error: electrophysiological evidence for separable inhibitory and sustained attention neural mechanisms producing error on go\/no-go tasks","volume":"21","author":"O\u2019Connell","year":"2009","journal-title":"J. Cogn. Neurosci."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib45","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.paid.2003.12.013","article-title":"The affective lability scales: development of a short-form measure","volume":"37","author":"Oliver","year":"2004","journal-title":"Personal. Individ. Differ."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib46","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1176\/ajp.2007.164.6.942","article-title":"The worldwide prevalence of ADHD: a systematic review and metaregression analysis","volume":"164","author":"Polanczyk","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib47","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1556-4029.2007.00603.x","article-title":"Potency of \u03949-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology","volume":"53","author":"Potter","year":"2008","journal-title":"J. Forensic Sci."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib48","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1177\/0269881108092393","article-title":"Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users","volume":"23","author":"Ramaekers","year":"2009","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib49","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1038\/sj.npp.1301068","article-title":"High-potency marijuana impairs executive function and inhibitory motor control","volume":"31","author":"Ramaekers","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib50","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1001\/jama.2013.282542","article-title":"Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000\u20132012","volume":"311","author":"Sacks","year":"2014","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib51","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/sleep\/29.12.1573","article-title":"Effects of atomoxetine and methylphenidate on sleep in children with ADHD","volume":"29","author":"Sangal","year":"2006","journal-title":"Sleep"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib52","unstructured":"Schoedel, K.A., Chen, N., Hilliard, A., White, L., Stott, C., Russo, E., Wright, S., Guy, G., Romach, M.K., Sellers, E.M., 2011. A Randomized , Double \u2010 Blind , Placebo \u2010 Controlled , Crossover Study to Evaluate the Subjective Abuse Potential and Cognitive Effects of Nabiximols Oromucosal Spray in Subjects with a History of Recreational Cannabis Use. Vol. 26, pp. 224\u2013236. http:\/\/dx.doi.org\/10.1002\/hup."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib53","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00415-012-6634-z","article-title":"Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis","volume":"260","author":"Serpell","year":"2013","journal-title":"J. Neurol."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib54","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1192\/bjp.bp.107.048827","article-title":"Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis","volume":"194","author":"Simon","year":"2009","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib55","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/1874473710801010081","article-title":"The chronic effects of cannabis on memory in humans: a review","volume":"1","author":"Solowij","year":"2008","journal-title":"Curr. Drug Abus. Rev."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib56","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.neuroimage.2010.04.274","article-title":"Significant decreases in frontal and temporal [11C]-raclopride binding after THC challenge","volume":"52","author":"Stokes","year":"2010","journal-title":"Neuroimage"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib57","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.neuroimage.2009.06.029","article-title":"Can recreational doses of THC produce significant dopamine release in the human striatum?","volume":"48","author":"Stokes","year":"2009","journal-title":"Neuroimage"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib58","first-page":"1","article-title":"Cannabis improves symptoms of ADHD","volume":"3","author":"Strohbeck-kuehner","year":"2008","journal-title":"Archive"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib59","unstructured":"Tamm, L., Epstein, J.N., Lisdahl, K.M., Tapert, S., Hinshaw, S.P., Arnold, L.E., Velanova, K., Abilkoff, H., Swanson, J.M., 2014. Impact of ADHD and Cannabis Use on Executive Functioning in Young Adults. Vol. 133, pp. 1\u201315. http:\/\/dx.doi.org\/10.1016\/j.drugalcdep.2013.08.001.Impact."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib60","first-page":"1","article-title":"The changes of the cognitive and psychomotor functions in the chronic cannabis users after a month of remission","volume":"26","author":"Umut","year":"2016","journal-title":"Klin. Psikofarmakol. Bul. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib61","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0925-4927(01)00104-4","article-title":"Cannabis induced dopamine release: an in-vivo SPECT study","volume":"107","author":"Voruganti","year":"2001","journal-title":"Psychiatry Res. - Neuroimaging"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib62","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/JCP.0b013e318267c304","article-title":"Does atomoxetine improve executive function, inhibitory control, and hyperactivity?","volume":"32","author":"Wehmeier","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib63","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1017\/S1092852900013687","article-title":"Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial","volume":"11","author":"Weisler","year":"2006","journal-title":"CNS Spectr."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib64","unstructured":"Weiss, M., 2007. Weiss Functional Impairment Rating Scale - Self Report (WFIRS-S)."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib65","series-title":"Attention-deficit Hyperactivity Disorder in Adults","author":"Wender","year":"1995"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib66","unstructured":"Wilens, T., 2004. Subtypes of ADHD at risk for substance abuse. ADHD subtypes and subgroups at risk for substance use disorders (NIDA). In: Proceedings of the Symposium at the Annual Meetings of the American Psychiatric Association. APA, New York, NY."},{"key":"10.1016\/j.euroneuro.2017.05.005_bib67","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"Br. Med. J."},{"issue":"Suppl 1","key":"10.1016\/j.euroneuro.2017.05.005_bib68","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.3109\/15622975.2011.600319","article-title":"ADHD and offenders","volume":"12","author":"Young","year":"2011","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.05.005_bib69","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1590\/S0100-879X2006000400001","article-title":"Cannabidiol, a Cannabis Sativa constituent, as an antipsychotic drug. Brazilian","volume":"39","author":"Zuardi","year":"2006","journal-title":"Braz. J. Med. Biol. Res."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X17302377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X17302377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T05:36:20Z","timestamp":1569389780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X17302377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":70,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0924977X17302377"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2017.05.005","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727683729.793535801","asserted-by":"object"}]},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabinoids in attention-deficit\/hyperactivity disorder: A randomised-controlled trial","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2017.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}